524516 Stock Overview
Manufactures, exports, and retails pharmaceuticals, medicinal chemicals, and botanical products in India. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bacil Pharma Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹61.31 |
52 Week High | ₹62.56 |
52 Week Low | ₹5.69 |
Beta | 0.67 |
1 Month Change | 41.14% |
3 Month Change | 134.54% |
1 Year Change | 1,031.18% |
3 Year Change | 990.93% |
5 Year Change | 2,980.90% |
Change since IPO | 1,999.66% |
Recent News & Updates
Recent updates
Shareholder Returns
524516 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 6.0% | 0.8% | -4.2% |
1Y | 1,031.2% | 39.7% | 19.1% |
Return vs Industry: 524516 exceeded the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: 524516 exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
524516 volatility | |
---|---|
524516 Average Weekly Movement | 4.3% |
Pharmaceuticals Industry Average Movement | 6.0% |
Market Average Movement | 6.2% |
10% most volatile stocks in IN Market | 9.0% |
10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 524516 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524516's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 3 | Ganpat Salekar | www.bacilpharma.co.in |
Bacil Pharma Limited manufactures, exports, and retails pharmaceuticals, medicinal chemicals, and botanical products in India. The company offers anti-anxiety medicine, antihistamines, chemical compounds, drugs, and herbal tablets and capsules. Bacil Pharma Limited was incorporated in 1987 and is based in Mumbai, India.
Bacil Pharma Limited Fundamentals Summary
524516 fundamental statistics | |
---|---|
Market cap | ₹361.12m |
Earnings (TTM) | ₹3.85m |
Revenue (TTM) | n/a |
93.8x
P/E Ratio0.0x
P/S RatioIs 524516 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
524516 income statement (TTM) | |
---|---|
Revenue | ₹0 |
Cost of Revenue | ₹0 |
Gross Profit | ₹0 |
Other Expenses | -₹3.85m |
Earnings | ₹3.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.65 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 9.7% |
How did 524516 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 13:04 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bacil Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|